Eidos Therapeutics (EIDX) Stock Rating Upgraded by Zacks Investment Research

Eidos Therapeutics (NASDAQ:EIDX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Monday, Zacks.com reports.

According to Zacks, “Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States. “

Other equities analysts also recently issued reports about the stock. ValuEngine downgraded shares of Eidos Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, December 17th. JPMorgan Chase & Co. downgraded shares of Eidos Therapeutics from an “overweight” rating to a “neutral” rating and set a $29.00 price objective for the company. in a research note on Wednesday, January 23rd. Finally, BMO Capital Markets initiated coverage on shares of Eidos Therapeutics in a research note on Friday, February 22nd. They set an “outperform” rating and a $28.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $27.00.

Shares of NASDAQ:EIDX opened at $25.01 on Monday. Eidos Therapeutics has a 12 month low of $8.89 and a 12 month high of $25.55.

Eidos Therapeutics (NASDAQ:EIDX) last issued its quarterly earnings data on Monday, April 15th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.01). As a group, analysts expect that Eidos Therapeutics will post -1.99 earnings per share for the current fiscal year.

In related news, insider Jonathan C. Fox sold 5,000 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $23.11, for a total value of $115,550.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Christine Siu sold 11,913 shares of the stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $19.66, for a total transaction of $234,209.58. The disclosure for this sale can be found here.

A number of hedge funds have recently added to or reduced their stakes in EIDX. Aisling Capital Management LP bought a new position in Eidos Therapeutics in the fourth quarter worth about $15,461,000. BlackRock Inc. raised its stake in Eidos Therapeutics by 385.1% in the third quarter. BlackRock Inc. now owns 727,698 shares of the company’s stock worth $7,264,000 after buying an additional 577,698 shares in the last quarter. Victory Capital Management Inc. bought a new position in Eidos Therapeutics in the fourth quarter worth about $2,835,000. Hillhouse Capital Advisors Ltd. bought a new position in Eidos Therapeutics in the fourth quarter worth about $2,458,000. Finally, Vanguard Group Inc raised its stake in Eidos Therapeutics by 297.3% in the third quarter. Vanguard Group Inc now owns 198,673 shares of the company’s stock worth $1,983,000 after buying an additional 148,673 shares in the last quarter. 30.15% of the stock is owned by institutional investors.

Eidos Therapeutics Company Profile

Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.

Read More: What is a put option?

Get a free copy of the Zacks research report on Eidos Therapeutics (EIDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Eidos Therapeutics (NASDAQ:EIDX)

Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit